Trinomab

About Trinomab

Trinomab Pharmaceutical is a clinical-stage biopharmaceutical company established in Zhuhai, China, in December 2015. The company was co-founded by Dr. Liao Huaxin, an immunologist and virologist with over 40 years of research experience, and Mr. Zheng Weihong, an entrepreneur with extensive experience in biopharmaceutical commercialization and corporate management. Dr. Liao, who serves as Chairman and CTO, holds a Ph.D. from the University of North Carolina at Chapel Hill and was formerly a professor at Duke University, bringing deep expertise in vaccine development and antibody research. Mr. Zheng, the Vice Chairman and General Manager, holds an MBA from Peking University and previously served as General Manager at Beijing Chia Tai Lvzhou Pharmaceutical, where he led the commercialization of multiple anti-infective drugs.

The company focuses on developing fully human monoclonal antibody drugs as alternatives to traditional blood plasma-derived products for treating infectious diseases, autoimmune disorders, and malignant tumors. Its business model revolves around the research, development, manufacturing, and future commercialization of these novel antibody therapies. Revenue is currently generated from technology patent transfers, with its first product, Siltartoxatug (TNM002), approved in early 2025, marking the beginning of pharmaceutical sales. Trinomab operates a GMP-certified antibody production facility in Zhuhai to support its clinical trials and future commercial production.

Trinomab's core asset is its proprietary HitmAb® technology platform, a fourth-generation system for discovering and developing natural, fully human monoclonal antibodies. This platform aims to produce therapies with high safety profiles and strong affinity, mitigating issues like anti-drug antibody (ADA) reactions common with traditional antibody drugs. The company has built a robust pipeline of over 20 antibody candidates. Its lead product, Siltartoxatug (TNM002), is a first-in-class monoclonal antibody for tetanus prophylaxis, which received marketing approval in China. Another key candidate, TNM001, is a long-acting antibody for preventing respiratory syncytial virus (RSV) and is currently in Phase III clinical trials. Other pipeline assets in various clinical stages target conditions such as varicella-zoster virus (TNM005), human cytomegalovirus (TNM006), and cancer pain (TNM009).

The company has secured significant funding to advance its pipeline, including a $69.3 million Series A round in April 2021 led by GL Ventures, and a pre-IPO round of approximately 750 million RMB in November 2022. Trinomab has made progress toward an IPO on the STAR Market of the Shanghai Stock Exchange.